Interventional Cardiology Devices Market Size, Share & Trends Analysis Report By Product (Coronary Stents, PTCA Balloon Catheters, Accessory Devices), By Region,- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global interventional cardiology devices market size was exhibited at USD 13.91 billion in 2023 and is projected to hit around USD 27.67 billion by 2033, growing at a CAGR of 7.12% during the forecast period 2024 to 2033.

Key Takeaways:

• North America dominated the market with the largest revenue share of around 37.0% in 2023.
• The Asia Pacific region is expected to advance at the fastest CAGR of 7.9% over the forecast period.
• The coronary stents segment dominated the market with the largest revenue share of 65.0% in 2023.

Report Scope of The Interventional Cardiology Devices Market

Technological advancements, the launch of new products, favorable government policies, and increasing incidence rates of heart valve disease, Carotid Artery Disease (CAD), and peripheral artery disease are expected to propel market growth. Moreover, the increasing penetration & awareness about Minimally Invasive Surgeries (MIS) among the global population is further expected to drive market growth. According to the National Center for Biotechnology Information (NCBI), over ten units are currently undertaking cardiac MIS in the UK National Health Service (NHS).

Government initiatives to increase the accessibility and cost of IC treatments, such as the Ayushman Bharat Yojana in India, would encourage patient numbers to rise substantially during the forecast period. In September 2018, the Indian government introduced the largest publicly financed healthcare program in the world, the Ayushman Bharat Yojana. Focusing on disadvantaged families in rural areas, the government hopes to create a network of primary healthcare facilities centered in the community and offer insurance coverage for secondary and tertiary services to roughly half of the nation's residents.

Non-profit medical associations are also contributing to the growth of the market. For instance, in September 2023, the Society for Cardiovascular Angiography & Interventions (SCAI), a leading non-profit medical society, is coming up with the 6th Annual SCAI Interface in Interventional Cardiology in Mumbai, India, in the presence of leading interventional cardiologists from around the globe.

The COVID-19 pandemic had a significant impact on the interventional cardiology device market. The industry experienced a decline in demand as elective procedures were postponed or canceled to curb the spread of the virus. As per data from the British Cardiovascular Intervention Society, PCI volumes in the UK decreased by 49% during the lockdown phase of the pandemic. This decline was most pronounced in PCI for stable angina, which witnessed a 66% volume reduction. Other studies showed similar declines in interventional cardiology procedures in other nations. For instance, a study in the U.S. highlighted that PCI volumes decreased by 30% in the first few months of the pandemic.

Segments:

Interventional Cardiology Devices Market ByProduct Insights

The coronary stents segment dominated the market with the largest revenue share of 65.0% in 2023. DES makes up the majority of sales in the coronary stent category. The market has benefited from the introduction of next-generation DES such as the XIENCE series by Abbott Laboratories, Medtronic's Resolute Onyx, and many other well-known stents, including the SYNERGY and Orsiro DES from Boston Scientific and BIOTRONIK, respectively. These stents provide superior deliverability, stent integrity, and reduced rates of problems compared to their older counterparts.

In August 2023, Medtronic announced that it had received the European CE Mark approval for its Onyx Frontier Drug-Eluting Stent (DES). Also, Onyx Frontier had received U.S. FDA approval in May 2023. This DES offers significant improvements over the company’s previous generation Resolute Onyx DES family. It features an enhanced delivery system designed to improve deliverability and increase acute performance.

The market for PTCA balloon catheters will also continue to rise significantly throughout the forecast period, partly because more PCI procedures are expected to be performed, especially in places such as India, China, and Latin American nations, where untreated CAD is more prevalent. The total number of IC processes significantly influences the growth of the market for companion devices. As more patients in the covered regions become eligible for Percutaneous Coronary Intervention (PCI), accessory device sales are expected to increase, driving segment revenues.

As several devices must be used in every IC method, the accessory device market is rather large, despite typically low ASPs compared to other device categories. For instance, in August 2023, Kossel Medtech launched its first peripheral product, the Falspeed percutaneous transluminal angioplasty (PTA) balloon dilatation catheter, approved by the National Medical Products Administration (NMPA) in June 2023.

The company further announced that the PTA balloon catheter is also registered under the FDA and is expected to receive 510(K) clearance by the end of 2023. In another instance, in February 2023, CERENOVUS, a part of Johnson & Johnson Medical Devices Companies, launched EMBOGUARD. This next-generation balloon guide catheter has been indicated for use in patients with acute ischemic stroke and also in endovascular procedures.

The intravascular imaging catheters and pressure guidewires segment is expected to expand at the fastest CAGR of 8.5% over the forecast period. These devices are used in minimally invasive procedures, which are becoming increasingly popular due to their lower risk of complications, shorter recovery times, and advancements in intravascular imaging technologies, such as Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT). They offer more detailed images of the heart and coronary arteries, which can help physicians make more informed treatment decisions.

Several developments support the growth of this segment. For instance, Intravascular Imaging Incorporated (i3) collaborated with Massachusetts General Hospital (Boston) to design a 3-French NIRF-IVUS catheter. The product, launched in July 2023, helps visualize cellular and molecular details, which underlines the pathophysiologic progression of arterial dissections, coronary lesions, and coronary transplant vasculopathy.

The reimbursement scenario is also favorable for atherectomy, contributing to its growth. For instance, in January 2023, the French National Authority for Health (HAS) released recommendations regarding add-on reimbursement of medical devices and aids, which included opinions concerning peripheral vascular and cardiovascular devices. The reimbursement suggestions had been gathered from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS).

Interventional Cardiology Devices Market By Regional Insights

North America dominated the market with the largest revenue share of around 37.0% in 2023, owing to the high prevalence of cardiovascular diseases, such as coronary artery disease and heart failure, in the region. This is due to several factors, including the high prevalence of obesity, smoking, and diabetes among the regional population. Advanced healthcare infrastructure, including the establishment of several hospitals and clinics, and high disposable incomes are other factors propelling the regional market growth.

For instance, in April 2023, New York-Presbyterian Hudson Valley Hospital announced the launch of an Interventional Cardiology Program. Along with this, the facility also launched an advanced cardiac catheterization lab to provide advanced cardiac intervention services and an expanded access to leading specialists and care. Such initiatives are expected to drive the growth of the interventional cardiology devices market.

On the other hand, the Asia Pacific region is expected to advance at the fastest CAGR of 7.9% over the forecast period. This growth can be attributed to several factors, including the increasing incidence of coronary artery disease (CAD) and improved screening measures for this disorder. Furthermore, the region's economic development, augmented government investment in healthcare, favorable reimbursement policies in countries such as South Korea and Australia, and the expansion of healthcare infrastructure in India and China have contributed to this trend.

Additionally, the escalating prevalence of various CAD risk factors, including unhealthy diets, smoking, and sedentary lifestyles, has played a vital role in driving regional growth. The Chinese government implemented a centralized procurement procedure for high-value medical consumables in January 2021, significantly reducing the costs of DES. In November 2021, Medtronic launched the Arctic Front Cardiac Cryoablation Catheter System in India. It became the first and only cryoballoon catheter for treating atrial fibrillation (AF) approved by the Central Drugs Standard Control Organization (CDSCO).

In another development, in February 2023, Swiss Interventional Systems (SIS) Medical AG launched the OPN NC percutaneous transluminal coronary angioplasty (PTCA) catheter in the U.S. It is a dilatation catheter with Twin-Wall technology that was approved by the FDA in March 2023. Also, in September 2023, Lepu Medical Technology Co., Ltd. announced that it had recieved approval from the NMPA to launch its peripheral cutting balloon for treating PAD (peripheral arterial disease) in Beijing, China.

Europe is anticipated to witness exponential growth during the forecast period due to ongoing innovations, regional approval of newer technologies such as next-generation DES and BRS, and subsequent acceptance of these expensive technologies due to their benefits in revascularization treatments. For instance, in May 2023, the European Society of Cardiology collaborated with Europa Group and PCR to reduce the global spread of cardiovascular disease. In May 2023, Canon Medical joined an advanced course in interventional cardiovascular medicine at the EuroPCR conference in France, to learn about the latest dose-reduction devices & tools and cutting-edge technologies.

Some of the prominent players in the Interventional cardiology devices market include:

• Abbott Laboratories
• Medtronic
• Boston Scientific
• Spectranetics
• Cardinal Health
• Philips Healthcare
• Terumo
• Alvimedica
• Teleflex Medical
• B. Braun
• Biosensors Internationa
• Meril Life Sciences
• BIOTRONIK
• ACIST Medical Systems
• ASAHI INTECC
• CID Vascular
• Cook Medical
• Medinol
• Merit Medical Systems
• NuMED
• OpSens
• Vascular Solutions
• Zeon Medical

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global interventional cardiology devices market.

Product

• Coronary Stents

• • DES
  • BMS
  • BRS

• PTCA Balloon Catheters

• • Normal
  • Specialty (Includes cutting, scoring, and lithotripsy balloons)
  • DCB

• Accessory Devices

• • PTCA Guidewires (Workhorse, Specialty)
  • Diagnostic Catheters
  • PTCA Guiding Catheters
  • Introducer Sheaths

• Intravascular Imaging Catheters and Pressure Guidewires (IVUS Catheters, OCT Catheters, FFR Guidewires)

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)